Olema Pharmaceuticals
Olema Pharmaceuticals is a United States-based biotechnology company running 2 late-stage cancer trials in HR-positive / HER2-negative breast cancer.
Overview
Olema Pharmaceuticals, based in San Francisco, the United States, is a biotechnology company listed as NASDAQ: OLMA. Olema Oncology is a clinical-stage biopharmaceutical company focused on discovering, developing and commercialising targeted therapies for breast cancer, drawing on expertise in endocrine-driven cancers and nuclear receptors. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3) in HR-positive / HER2-negative breast cancer. The largest, NCT07085767 (Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer), plans to enrol 1000 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyForward Pharmaceuticals
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyTreadwell Therapeutics
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyOncolytics Biotech
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyShenzhen Ionova Life Sciences
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyXuanzhu Biopharmaceutical
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyEllipses Pharma
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyNuvation Bio
Shares HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.